firocoxib has been researched along with uric acid in 4 studies
*Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN. [MeSH]
*Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN. [MeSH]
Studies (firocoxib) | Trials (firocoxib) | Recent Studies (post-2010) (firocoxib) | Studies (uric acid) | Trials (uric acid) | Recent Studies (post-2010) (uric acid) |
---|---|---|---|---|---|
102 | 43 | 71 | 27,980 | 1,717 | 9,982 |
Protein | Taxonomy | firocoxib (IC50) | uric acid (IC50) |
---|---|---|---|
Solute carrier family 2, facilitated glucose transporter member 9 | Homo sapiens (human) | 300 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hanson, PD; Hazewinkel, HA; Pollmeier, M; Theyse, LF; van den Brom, WE | 1 |
Drag, M; Hanson, PD; Kunkle, BN; Romano, D | 1 |
Al-Nadaf, S; Budsberg, SC; Cathcart, CJ; Johnston, SA; Reynolds, LR | 1 |
Beugnet, F; de Salazar Alcalá, AG; Dehman, A; Gioda, L | 1 |
4 trial(s) available for firocoxib and uric acid
Article | Year |
---|---|
Comparison of the effects of firocoxib, carprofen and vedaprofen in a sodium urate crystal induced synovitis model of arthritis in dogs.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Carbazoles; Cross-Over Studies; Dog Diseases; Dogs; Female; Lameness, Animal; Male; Naphthalenes; Propionates; Sulfones; Synovitis; Time Factors; Uric Acid | 2008 |
Firocoxib efficacy preventing urate-induced synovitis, pain, and inflammation in dogs.
Topics: 4-Butyrolactone; Animals; Carbazoles; Cyclooxygenase 2 Inhibitors; Dog Diseases; Dogs; Female; Lameness, Animal; Male; Meloxicam; Severity of Illness Index; Sulfonamides; Sulfones; Synovitis; Thiazines; Thiazoles; Treatment Outcome; Uric Acid | 2007 |
Efficacy of ABT-116, an antagonist of transient receptor potential vanilloid type 1, in providing analgesia for dogs with chemically induced synovitis.
Topics: 4-Butyrolactone; Analgesia; Animals; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Female; Indazoles; Injections, Intra-Articular; Lameness, Animal; Male; Phenylurea Compounds; Stifle; Sulfones; Synovitis; TRPV Cation Channels; Uric Acid | 2012 |
Assessment of the efficacy of firocoxib (Previcox®) and grapiprant (Galliprant®) in an induced model of acute arthritis in dogs.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Dog Diseases; Dogs; Lameness, Animal; Random Allocation; Sulfones; Sulfonylurea Compounds; Uric Acid | 2019 |